Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...

The diet has garnered attention for its potential to prevent modern-day health issues like obesity, diabetes, and heart ...

At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than ...

EMCKD severity is linked to cognitive impairment risk, with proteinuria a key predictor. Learn more about the findings from ...

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...

Maze Therapeutics could be set to challenge Vertex Pharmaceuticals as its kidney disease drug has shown benefit in a Phase II ...

Withdrawing immunosuppression after achieving remission in LN should be done gradually and requires careful patient selection ...

Earlier in March 2026, Vertex Pharmaceuticals reported positive pre-specified Week 36 interim Phase 3 RAINIER data for ...

Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...

Maze Therapeutics (MAZE) stock plunged even as the company posts positive Phase 2 trial data for lead asset MZE829 in ...

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support ...